Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL versus HYDROMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL versus HYDROMOX.
ENDURONYL vs HYDROMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+-Cl− symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion.
ENDURONYL (methyclothiazide and deserpidine) is a fixed-dose combination antihypertensive. Typical adult dose: 1 tablet (methyclothiazide 5 mg / deserpidine 0.25 mg) orally once daily. Dose may be increased to 2 tablets once daily if needed.
50-100 mg orally once daily; may increase to 200 mg/day for severe edema.
None Documented
None Documented
Terminal elimination half-life 10-15 hours; clinically, may require 3-5 days to reach steady state in hypertension management.
Terminal elimination half-life: 6-9 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Primarily renal excretion; ~50% unchanged, ~25% as deserpidine metabolites, 20% biliary-fecal.
Renal: 70% unchanged via tubular secretion; biliary/fecal: <10%
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic